单唾液酸四己糖神经节苷脂联合舒血宁治疗脑梗死疗效观察

目的观察单唾液酸四己糖神经节苷脂联合舒血宁治疗急性脑梗死的临床效果及对患者炎症因子水平的影响。方法急性脑梗死患者126例随机分为对照组和观察组各63例，对照组在常规治疗基础上给予舒血宁20mL，静脉滴注，1次／d；观察组在对照组治疗基础上给予单唾液酸四己糖神经节苷脂40mg，静脉滴注，1次／d，2组疗程均为14d。2组分别于治疗前及治疗第15天行神经功能缺损评分（NationalInstituteofHealthStrokeScale，NIHss）和日常生活活动能力评分（ActivityofDailyLivingScale，ADL），检测肿瘤坏死因子-α（tumornecrosisfactor-α，TNF—α）、白细胞介素-6（interleukin-6，IL-6）和C反应蛋白（C-reactiveprotein，CRP）水平，并比较疗效。结果2组治疗后NIHSS和ADL评分，TNF-α、IL-6和CRP水平较治疗前降低（P〈0．05），观察组各指标改善优于对照组（P〈0．05）；观察组总有效率（93．7％）优于对照组（73．0％）（P〈O．05）。结论单唾液酸四己糖神经节苷脂联合舒血宁可改善急性脑梗死患者神经功能缺损，提高生活自理能力，减轻炎症反应，起到减少脑组织损伤，保护患者神经功能的作用。

Effect of monosialotetrahexosylganglioside combined with Shuxuening on cerebral infarction

Objective To observe the clinical effect of monosialotetrahexosylganglioside （GM1） combined with Shuxuening and its influence on inflammatory factors. Methods A total of 126 patients with acute cerebral infarction were randomly divided into observation group and control group, with 63 patients in each group. Control group was intravenously injected Shuxuening 20 mL once a day besides the routine therapy, and observation group was intravenously injected GM1 40 mg once a day in addition to the therapy in control group, totally for 14 days. The National Institute of Health Stroke Scale （NIHSS）, Activity of Daily Living Scale （ADL）, tumor necrosis factor-α（TNF-α）, interleukin-6 （IL-6） and C-reactive protein （CRP） were evaluated and detected before treatment and by day 15 after treatment. The therapeutic effect was compared between two groups. Results The NIHSS, ADL, TNF-α, IL-6 and CRP were lower after treatment than those before treatment in both groups （P〈0. 05）, which was much more significant in observation group than that in control group （P〈0.05）. The total therapeutic effect was 93.7% in observation group, higher than that in control group （73.0%） （P〈0.05）. Conclusions The combination of GM1 and Shuxuening can reduce brain tissue injury and protect neurological function by improving ADL and reducing inflammatory reaction and cognitive impairments.